Cargando…

A Comparison of the Efficacy of 5 mg Olanzapine and Aprepitant in the Prevention of Multiple-Day Cisplatin Chemotherapy-Induced Nausea and Vomiting

OBJECTIVE: The significance of this article is to talk about aprepitant and olanzapine 5 mg, compare them, and deeply explore the safety or effectiveness during the whole process of multiple-day cisplatin chemotherapy-induced vomiting and nausea. METHODS: This trial was randomized and prospective. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Guang, Jin, Yilan, Jiang, Ying, Zhao, Juan, Jiang, Caihong, Zhang, Zewei, Zhao, Lanzhen, Li, Hui, Chen, Feng, Wang, Jing, Fan, Hui, Li, Zhenhao, Jia, Yongqiang, Jin, Gaowa, Li, Quanfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473898/ https://www.ncbi.nlm.nih.gov/pubmed/36128262 http://dx.doi.org/10.1155/2022/5954379

Ejemplares similares

Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study
por: Gao, Jiali, et al.
Publicado: (2022)

Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV
por: Jin, Yilan, et al.
Publicado: (2021)

A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy
por: Jin, Yilan, et al.
Publicado: (2023)

An Update in Our Understanding of the Relationships Between Gene Polymorphisms and Chemotherapy-Induced Nausea and Vomiting
por: Jin, Yilan, et al.
Publicado: (2021)

Evaluation of a Neurokinin-1 Antagonist in Preventing Multiple-day Cisplatin-induced Nausea and Vomiting
por: Li, Quanfu, et al.
Publicado: (2018)

Olanzapine 5 mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy
por: Wang, Jun, et al.
Publicado: (2022)

Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study
por: Kawazoe, Hitoshi, et al.
Publicado: (2018)

Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia
por: Li, Quanfu, et al.
Publicado: (2021)

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
por: Chrisp, Paul
Publicado: (2007)

The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting
por: Emami, Hamid, et al.
Publicado: (2015)

The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis
por: Liu, Yingchao, et al.
Publicado: (2023)

Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial
por: Wang, De-Shen, et al.
Publicado: (2021)

A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting
por: Wang, Xiao-fei, et al.
Publicado: (2014)

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
por: Langford, Patrick, et al.
Publicado: (2010)

Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer
por: Wang, Wenxian, et al.
Publicado: (2018)

Olanzapine: An Antiemetic Option for Chemotherapy-Induced Nausea and Vomiting
por: Brafford, Megan V., et al.
Publicado: (2014)

Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy
por: Ando, Yosuke, et al.
Publicado: (2015)

Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
por: Kang, Jin Hyoung, et al.
Publicado: (2020)

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
por: Tan, Lijun, et al.
Publicado: (2009)

Olanzapine in the Treatment of Refractory Nausea and Vomiting in Palliative Care Settings
por: Gupta, Nishkarsh, et al.
Publicado: (2018)

Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study
por: Shivaprakash, G., et al.
Publicado: (2017)

Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer
por: Watanabe, Yuko, et al.
Publicado: (2021)

Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis
por: Chelkeba, Legese, et al.
Publicado: (2017)

A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients
por: Jang, Geundoo, et al.
Publicado: (2013)

Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
por: Lim, Chae Seong, et al.
Publicado: (2013)

Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK
por: Humphreys, Samantha, et al.
Publicado: (2013)

Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer
por: Fujiwara, Satoe, et al.
Publicado: (2015)

Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: An updated systematic review and meta-analysis
por: Qiu, Tingting, et al.
Publicado: (2020)

Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles
por: Qiu, Tingting, et al.
Publicado: (2021)

Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis
por: Zhang, Min, et al.
Publicado: (2023)

The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone
por: Lee, Se-Jin, et al.
Publicado: (2012)

The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
por: Eghbali, Aziz, et al.
Publicado: (2023)

Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia
por: Yoo, Jae Hwa, et al.
Publicado: (2018)

Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016)

Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial
por: Moon, Hyoung Yong, et al.
Publicado: (2014)

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan
por: Osman, Alaa A.M., et al.
Publicado: (2018)

Cisplatin-Induced Nausea and Vomiting: Effect of Herbal Medicines
por: Shin, Yuchan, et al.
Publicado: (2022)

Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma
por: Giagnuolo, Giovanna, et al.
Publicado: (2019)

Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting
por: Nijstad, A. Laura, et al.
Publicado: (2022)

The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis
por: Wang, Dong-Yang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ef2ffk7tc5hs3lartpbcnf3kqk